|
US4464467A
(en)
*
|
1982-07-26 |
1984-08-07 |
Bristol-Myers Company |
Antitumor antibiotics produced by new streptomyces
|
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
|
GB9818732D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
|
DK1413582T3
(en)
|
1998-08-27 |
2006-07-17 |
Spirogen Ltd |
Dimer pyrrolobenzodiazepines
|
|
US6909006B1
(en)
|
1999-08-27 |
2005-06-21 |
Spirogen Limited |
Cyclopropylindole derivatives
|
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
|
ES2398975T3
(en)
|
2004-03-01 |
2013-03-25 |
Spirogen Sàrl |
11-Hydroxy-5H-pyrrolo [2,1-c] [1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines
|
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
JP5166861B2
(en)
|
2004-03-09 |
2013-03-21 |
スピロゲン リミティッド |
Pyrrolobenzodiazepine
|
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
MX368648B
(en)
|
2010-04-15 |
2019-10-09 |
Seattle Genetics Inc |
Pyrrolobenzodiazepines used to treat proliferative diseases.
|
|
NZ602932A
(en)
|
2010-04-15 |
2014-08-29 |
Seattle Genetics Inc |
Targeted pyrrolobenzodiazapine conjugates
|
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
|
MX341524B
(en)
|
2011-09-20 |
2016-08-24 |
Medimmune Ltd |
Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates.
|
|
KR101891859B1
(en)
|
2011-10-14 |
2018-08-24 |
메디뮨 리미티드 |
Pyrrolobenzodiazepines
|
|
EA029046B1
(en)
|
2011-10-14 |
2018-02-28 |
Медимьюн Лимитед |
Pyrrolobenzodiazepines and intermediates for the preparation thereof, synthesis methods thereof
|
|
EP2751110B1
(en)
|
2011-10-14 |
2017-04-19 |
MedImmune Limited |
Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
AU2012322613B2
(en)
|
2011-10-14 |
2016-04-21 |
Medimmune Limited |
Pyrrolobenzodiazepines and targeted conjugates
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2014057074A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
SMT201800346T1
(en)
|
2012-10-12 |
2018-09-13 |
Medimmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SI2906253T1
(en)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
|
WO2014057122A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
EP2906249B1
(en)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
|
PT2906298T
(en)
|
2012-10-12 |
2018-12-28 |
Medimmune Ltd |
PYROLOBENZODIAZEPIN-ANTIBODY CONJUGATES
|
|
ES2713164T3
(en)
|
2012-10-12 |
2019-05-20 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
ES2871001T3
(en)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugates of pyrrolobenzodiazepines and antibodies
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2018192944A1
(en)
|
2017-04-18 |
2018-10-25 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
CA3057748A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
ES2988683T3
(en)
|
2017-06-14 |
2024-11-21 |
Adc Therapeutics Sa |
Dosage guidelines for the administration of an anti-CD19 CAF
|
|
SG11202000358YA
(en)
|
2017-08-18 |
2020-02-27 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MX2021010477A
(en)
|
2019-03-15 |
2021-10-01 |
Medimmune Ltd |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer.
|